Ipamorelin: the selective GH secretagogue with the cleanest profile

A five–amino-acid peptide that pushes growth hormone without the side-show.

TL;DR

• Ipamorelin is a five–amino-acid peptide that nudges your pituitary to release growth hormone.
• In published studies it does not raise cortisol (the stress hormone) or appetite the way older secretagogues do.
• It is most often used in combination with CJC-1295, which works on a different pathway.

What it is

Ipamorelin is a synthetic peptide built from five amino acids. It belongs to a family called growth hormone secretagogues (in plain English: molecules that prompt the pituitary gland to release growth hormone). The body's natural version of this signal is ghrelin — the same peptide that tells you you're hungry. Ipamorelin copies the growth-hormone-releasing part of ghrelin's job and skips the hunger part. That selectivity is the headline. It is one of the cleanest tools in this category by side-effect profile.

How it works

Picture the pituitary gland as a small light switch high in your brain. Ghrelin can flip that switch, but it also flips a few others — appetite, cortisol, prolactin. Ipamorelin docks at the same switch ghrelin uses (the GHSR-1a receptor, the ghrelin receptor) but ignores the side switches. The result is a clean pulse of growth hormone without the hunger spike or the cortisol bump. Cortisol is your body's main stress hormone, so keeping it flat matters for sleep and recovery (Raun et al., Eur J Endocrinol, 1998).

Who asks about it

People come to ipamorelin when they want the recovery, sleep, and body-composition signals associated with growth hormone but without the side effects of older secretagogues like GHRP-2 or GHRP-6, both of which spike hunger and cortisol. It also comes up in conversations about pairing peptides — ipamorelin is the standard partner for CJC-1295.

What the research says

In a foundational 1998 paper, ipamorelin produced a growth hormone release similar to GHRP-6 but without raising cortisol or prolactin in healthy volunteers (Raun et al., 1998). Later reviews have echoed the selectivity finding and described ipamorelin as the cleanest of the GHSR-1a agonists studied to date (Sigalos & Pastuszak, Sex Med Rev, 2018). Most evidence is short-term and in healthy adults; long-term human outcomes remain understudied.

What to know before considering it

Ipamorelin is generally well-tolerated in physician-supervised protocols; individual response varies. Common reported effects include mild injection-site reactions and short-lived flushing. It should not be used in active cancer, during pregnancy, or alongside high-dose corticosteroids without specialist input. Baseline IGF-1 is typically checked before starting and rechecked after several weeks. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed physician's evaluation.

The Halftime POV

Ipamorelin is the kind of tool that earns its place by what it doesn't do. No hunger spike, no cortisol bump, no prolactin shift. Combined with the right upstream signal, it gives physicians a precise way to support the growth-hormone axis in adults whose own pulses have flattened with age — without the noise that older peptides bring.

Related reading:

• CJC-1295: what this modified GHRH peptide is
• CJC-1295 + Ipamorelin: why they are often combined
• What are peptides? A plain-English primer

---

FAQ

Q: What is ipamorelin? A: Ipamorelin is a five–amino-acid peptide that prompts the pituitary gland to release growth hormone. It is called selective because, in published studies, it does not raise cortisol or appetite the way older secretagogues do.

Q: Is ipamorelin FDA-approved? A: No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed prescriber's evaluation.

Q: How is ipamorelin different from CJC-1295? A: Both push growth hormone, but they pull different levers. CJC-1295 mimics the upstream signal (GHRH). Ipamorelin mimics ghrelin, the body's hunger signal. Combining them creates a stronger pulse than either alone.

Q: Does ipamorelin make you hungry? A: In published studies on healthy adults, ipamorelin did not raise appetite the way older ghrelin-mimicking peptides did. Individual response varies.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Ipamorelin, the first selective growth hormone secretagogue — Raun et al., Eur J Endocrinol, 1998
• Beyond the Androgen Receptor: The Role of Growth Hormone Secretagogues — Sigalos & Pastuszak, Sex Med Rev, 2018

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.